Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1998 1
1999 7
2000 17
2001 8
2002 11
2003 11
2004 7
2005 11
2006 13
2007 10
2008 10
2009 5
2010 5
2011 6
2012 5
2013 8
2014 10
2015 4
2016 2
2017 3
2018 8
2019 8
2020 8
2021 9
2022 5
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Results by year

Filters applied: . Clear all
Page 1
Zaleplon.
[No authors listed] [No authors listed] 2023 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000323 Free Books & Documents. Review.
Little information is available on the use of zaleplon during breastfeeding. A safety scoring system finds zaleplon to be not recommended during breastfeeding.[1] However, the low levels of zaleplon in breastmilk and its short half-life indicate that amounts …
Little information is available on the use of zaleplon during breastfeeding. A safety scoring system finds zaleplon to be not …
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, Kurtulmus A, Tomlinson A, Mitrova Z, Foti F, Del Giovane C, Quested DJ, Cowen PJ, Barbui C, Amato L, Efthimiou O, Cipriani A. De Crescenzo F, et al. Lancet. 2022 Jul 16;400(10347):170-184. doi: 10.1016/S0140-6736(22)00878-9. Lancet. 2022. PMID: 35843245 Free article.
Primary outcomes were efficacy (ie, quality of sleep measured by any self-rated scale), treatment discontinuation for any reason and due to side-effects specifically, and safety (ie, number of patients with at least one adverse event) both for acute and long-term tr …
Primary outcomes were efficacy (ie, quality of sleep measured by any self-rated scale), treatment discontinuation for any reason and due to …
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery.
Atkin T, Comai S, Gobbi G. Atkin T, et al. Pharmacol Rev. 2018 Apr;70(2):197-245. doi: 10.1124/pr.117.014381. Pharmacol Rev. 2018. PMID: 29487083 Review.
Although the GABAergic benzodiazepines (BZDs) and Z-drugs (zolpidem, zopiclone, and zaleplon) are FDA-approved for insomnia disorders with a strong evidence base, they have many side effects, including cognitive impairment, tolerance, rebound insomnia upon discontin …
Although the GABAergic benzodiazepines (BZDs) and Z-drugs (zolpidem, zopiclone, and zaleplon) are FDA-approved for insomnia disorders …
Drugs for chronic insomnia.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6. doi: 10.58347/tml.2023.1667a. Med Lett Drugs Ther. 2023. PMID: 36630579 No abstract available.
Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis.
Yue JL, Chang XW, Zheng JW, Shi L, Xiang YJ, Que JY, Yuan K, Deng JH, Teng T, Li YY, Sun W, Sun HQ, Vitiello MV, Tang XD, Zhou XY, Bao YP, Shi J, Lu L. Yue JL, et al. Sleep Med Rev. 2023 Apr;68:101746. doi: 10.1016/j.smrv.2023.101746. Epub 2023 Jan 14. Sleep Med Rev. 2023. PMID: 36701954 Review.
Primary outcomes included sleep latency (SL), awake time after sleep onset (WASO) and discontinuation for adverse events (AED), and secondary outcomes included total sleep time (TST), sleep efficiency (SE), sleep quality (SQ) and adverse events (ADE). ...MRAs may al …
Primary outcomes included sleep latency (SL), awake time after sleep onset (WASO) and discontinuation for adverse events (AED), and s …
Zaleplon: a review of its use in the treatment of insomnia.
Dooley M, Plosker GL. Dooley M, et al. Drugs. 2000 Aug;60(2):413-45. doi: 10.2165/00003495-200060020-00014. Drugs. 2000. PMID: 10983740 Review.
Zaleplon 20 mg, however, impaired psychomotor function and memory immediately after the dose but next-day effects were not observed. ...In addition, tolerance to the effects of zaleplon is unlikely to develop when administered for the recommended treat
Zaleplon 20 mg, however, impaired psychomotor function and memory immediately after the dose but next-day effects were not obs
Review of Safety and Efficacy of Sleep Medicines in Older Adults.
Schroeck JL, Ford J, Conway EL, Kurtzhalts KE, Gee ME, Vollmer KA, Mergenhagen KA. Schroeck JL, et al. Clin Ther. 2016 Nov;38(11):2340-2372. doi: 10.1016/j.clinthera.2016.09.010. Epub 2016 Oct 15. Clin Ther. 2016. PMID: 27751669 Review.
Although the data on suvorexant are limited, this drug improves sleep maintenance and has mild adverse effects, including somnolence; residual daytime sedation has been reported, however. ...IMPLICATIONS: An ideal treatment for insomnia should help to improve sleep …
Although the data on suvorexant are limited, this drug improves sleep maintenance and has mild adverse effects, including somn …
Zaleplon.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2000 Mar 1;57(5):430-2. doi: 10.1093/ajhp/57.5.430. Am J Health Syst Pharm. 2000. PMID: 10711522 No abstract available.
Zolpidem: Efficacy and Side Effects for Insomnia.
Edinoff AN, Wu N, Ghaffar YT, Prejean R, Gremillion R, Cogburn M, Chami AA, Kaye AM, Kaye AD. Edinoff AN, et al. Health Psychol Res. 2021 Jun 18;9(1):24927. doi: 10.52965/001c.24927. eCollection 2021. Health Psychol Res. 2021. PMID: 34746488 Free PMC article. Review.
One of the most used of these hypnotics is zolpidem. However, zolpidem has a wide variety of adverse effects and has some special considerations noted in the literature. ...Still, zolpidem is considered a reasonable choice of therapy because it has a lower incidence …
One of the most used of these hypnotics is zolpidem. However, zolpidem has a wide variety of adverse effects and has some spec …
Safety of zaleplon in the treatment of insomnia.
Israel AG, Kramer JA. Israel AG, et al. Ann Pharmacother. 2002 May;36(5):852-9. doi: 10.1345/aph.1A086. Ann Pharmacother. 2002. PMID: 11978165 Review.
OBJECTIVE: To evaluate the safety of zaleplon, a quick-acting, rapidly eliminated nonbenzodiazepine (non-BZD) hypnotic, as described in clinical investigations of adult and/or elderly subjects. ...Additionally, rebound insomnia and other withdrawal effects have not …
OBJECTIVE: To evaluate the safety of zaleplon, a quick-acting, rapidly eliminated nonbenzodiazepine (non-BZD) hypnotic, as described …
185 results